141 related articles for article (PubMed ID: 38783331)
1. Prognostic and predictive value of interstitial lung abnormalities and EGFR mutation status in patients with non-small cell lung cancer.
Xu X; Zhu M; Wang Z; Li J; Ouyang T; Chen C; Huang K; Zhang Y; Gao YL
Cancer Imaging; 2024 May; 24(1):66. PubMed ID: 38783331
[TBL] [Abstract][Full Text] [Related]
2. Automated CT quantification of interstitial lung abnormality in patients with resectable stage I non-small cell lung cancer: Prognostic significance.
Chung JH; Park JM; Kim DH
Thorac Cancer; 2024 Jun; 15(16):1305-1311. PubMed ID: 38682806
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
4. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
5. Automated CT quantification of interstitial lung abnormality and interstitial lung disease according to the Fleischner Society in patients with resectable lung cancer: prognostic significance.
Ahn Y; Lee SM; Choi S; Lee JS; Choe J; Do KH; Seo JB
Eur Radiol; 2023 Nov; 33(11):8251-8262. PubMed ID: 37266656
[TBL] [Abstract][Full Text] [Related]
6. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
7. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
8. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
9. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
Nair JKR; Saeed UA; McDougall CC; Sabri A; Kovacina B; Raidu BVS; Khokhar RA; Probst S; Hirsh V; Chankowsky J; Van Kempen LC; Taylor J
Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
[TBL] [Abstract][Full Text] [Related]
10. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.
Zhu M; Yi J; Su Y; Zhang Y; Gao Y; Xu X; Zhang S; Zhang Y; Huang K
Thorac Cancer; 2023 Jul; 14(19):1874-1882. PubMed ID: 37232276
[TBL] [Abstract][Full Text] [Related]
11. Establishment and Evaluation of EGFR Mutation Prediction Model Based on Tumor Markers and CT Features in NSCLC.
Zhang H; He M; Wan R; Zhu L; Chu X
J Healthc Eng; 2022; 2022():8089750. PubMed ID: 35422977
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study.
Hida T; Hata A; Lu J; Valtchinov VI; Hino T; Nishino M; Honda H; Tomiyama N; Christiani DC; Hatabu H
Cancer Imaging; 2021 Jan; 21(1):14. PubMed ID: 33468255
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
16. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
[TBL] [Abstract][Full Text] [Related]
17. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
Digumarthy SR; Padole AM; Gullo RL; Sequist LV; Kalra MK
Medicine (Baltimore); 2019 Jan; 98(1):e13963. PubMed ID: 30608433
[TBL] [Abstract][Full Text] [Related]
18. Identification of predictors for brain metastasis in newly diagnosed non-small cell lung cancer: a single-center cohort study.
Park S; Lee SM; Ahn Y; Kim M; Suh CH; Do KH; Seo JB
Eur Radiol; 2022 Feb; 32(2):990-1001. PubMed ID: 34378076
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
20. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology.
Tu W; Sun G; Fan L; Wang Y; Xia Y; Guan Y; Li Q; Zhang D; Liu S; Li Z
Lung Cancer; 2019 Jun; 132():28-35. PubMed ID: 31097090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
